C
Celularity Inc. (CELU)
NCM – Real vaqt narxi. Valyuta: USD
0.69
-0.01 (-0.96%)
Bozor ochiq: Aug 12, 2026, 3:40 PM EDT
0.70
0.00 (0.00%)
Oldingi bozordan keyin: Aug 11, 2026, 4:10 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
0.69
-0.01 (-0.96%)
Bozor ochiq: Aug 12, 2026, 3:40 PM EDT
0.70
0.00 (0.00%)
Oldingi bozordan keyin: Aug 11, 2026, 4:10 PM EDT
Celularity Inc., hujayra va regenerativ tibbiyot kompaniyasi, yangi terapiyalar yordamida qarish bilan bog'liq kasalliklarni davolashga qaratilgan. Kompaniya uchta segment orqali faoliyat yuritadi: hujayra terapiyasi, degenerativ kasalliklar va BioBanking. U diabetik oyoq yarasi va Kron kasalligi uchun mezenximaga o'xshash yopishqoq stromal hujayralar, shu jumladan tayyorlash mumkin bo'lgan platsentadan olingan allogen hujayra terapiyasi mahsulot nomzodlarini ishlab chiqadi. Uning terapevtik dasturlari orasida autoimmun (Kron) va degenerativ kasalliklarni davolash uchun PDA-001; va ko'p skleroz, revmatoid artrit, insult va diabetik periferik neyropatiyani davolash uchun PDA-002 mavjud. Kompaniya shuningdek, Biovance, Biovance 3L, Rebound, Interfyl va Centaflex kabi jarrohlik va yara terapiyasi bozorlarida ishlatiladigan mahsulotlarni ishlab chiqaradi, sotadi va litsenziyalaydi; va LifebankUSA brendi ostida to'liq homiladorlikdan keyin kindik qoni va platsenta qonini va to'qimalarini yig'adi, qayta ishlaydi va saqlaydi. Celularity Inc. Sorrento Therapeutics, Inc. bilan litsenziyalangan CD19 CAR-T mahsulotlarini ishlab chiqish va tijoratlashtirish bo'yicha litsenziyalash shartnomasiga ega; va allogen hujayra terapiyasi nomzodlarini tadqiq qilishni qo'llab-quvvatlash uchun Regeneron Pharmaceuticals, Inc. bilan tadqiqot hamkorlik xizmatlari shartnomasiga ega. Celularity Inc. 1998-yilda tashkil etilgan va Florham Park, Nyu-Jersi shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Robert Joseph Hariri M.D., Ph.D. | Founder, CEO & Chairman |
| John Sprague | Acting Chief Financial Officer |
| Mr. Carlos Ramirez | SVP of Investor Relations |
| Mr. David Jakob Lemus CPA, M.S., MBA | Treasurer |
| Mr. Kyle Harold Fletcher Esq. | Chief Legal and Strategy Officer & Corporate Secretary |
| Mr. Steven N. Gordon Esq. | Chief Operating and Administrative Officer & Director |
| Mr. Tim Wilk | Senior Vice President of Technical Operations |
| Sharmila Koppisetti M.D. | Senior Vice President of Clinical Dev. Immunology & Drug Safety |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-07 | 8-K | form8-k.htm |
| 2026-07-29 | 8-K | form8-k.htm |
| 2026-06-30 | 8-K | form8-k.htm |
| 2026-06-25 | 8-K | form8-k.htm |
| 2026-06-12 | 8-K | form8-k.htm |
| 2026-06-03 | 8-K | form8-k.htm |
| 2026-05-28 | 8-K | form8-k.htm |
| 2026-05-15 | NT 10-Q | formnt10-q.htm |
| 2026-04-30 | 10-K | form10-k.htm |
| 2026-04-21 | 8-K | form8-k.htm |